Literature DB >> 18768964

Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.

Yuxian He1, Shuwen Liu, Jingjing Li, Hong Lu, Zhi Qi, Zhonghua Liu, Asim K Debnath, Shibo Jiang.   

Abstract

The fusogenic human immunodeficiency virus type 1 (HIV-1) gp41 core structure is a stable six-helix bundle formed by its N- and C-terminal heptad repeat sequences. Notably, the negatively charged residue Asp(632) located at the pocket-binding motif in the C-terminal heptad repeat interacts with the positively charged residue Lys(574) in the pocket formation region of the N-terminal heptad repeat to form a salt bridge. We previously demonstrated that the residue Lys(574) plays an essential role in six-helix bundle formation and virus infectivity and is a key determinant of the target for anti-HIV fusion inhibitors. In this study, the functionality of residue Asp(632) has been specifically characterized by mutational analysis and biophysical approaches. We show that Asp(632) substitutions with positively charged residues (D632K and D632R) or a hydrophobic residue (D632V) could completely abolish Env-mediated viral entry, while a protein with a conserved substitution (D632E) retained its activity. Similar to the Lys(574) mutations, nonconserved substitutions of Asp(632) also severely impaired the alpha-helicity, stability, and conformation of six-helix bundles as shown by N36 and C34 peptides as a model system. Furthermore, nonconserved substitutions of Asp(632) significantly reduced the potency of C34 to sequestrate six-helix bundle formation and to inhibit HIV-1-mediated cell-cell fusion and infection, suggesting its importance for designing antiviral fusion inhibitors. Taken together, these data suggest that the salt bridge between the N- and C-terminal heptad repeat regions of the fusion-active HIV-1 gp41 core structure is critical for viral entry and inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768964      PMCID: PMC2573276          DOI: 10.1128/JVI.01060-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

Review 1.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

2.  Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.

Authors:  Akira Otaka; Miki Nakamura; Daisuke Nameki; Eiichi Kodama; Susumu Uchiyama; Syota Nakamura; Hiroaki Nakano; Hirokazu Tamamura; Yuji Kobayashi; Masao Matsuoka; Nobutaka Fujii
Journal:  Angew Chem Int Ed Engl       Date:  2002-08-16       Impact factor: 15.336

3.  Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Authors:  Elisabetta Bianchi; Marco Finotto; Paolo Ingallinella; Renee Hrin; Anthony V Carella; Xiaoli S Hou; William A Schleif; Michael D Miller; Romas Geleziunas; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-29       Impact factor: 11.205

4.  Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.

Authors:  Antony S Dimitrov; John M Louis; Carole A Bewley; G Marius Clore; Robert Blumenthal
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

5.  HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.

Authors:  Francisco J Quintana; Doron Gerber; Sally C Kent; Irun R Cohen; Yechiel Shai
Journal:  J Clin Invest       Date:  2005-07-07       Impact factor: 14.808

6.  Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion.

Authors:  Shilong Wang; Joanne York; Wei Shu; Marisa O Stoller; Jack H Nunberg; Min Lu
Journal:  Biochemistry       Date:  2002-06-11       Impact factor: 3.162

7.  Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.

Authors:  Hongmei Mo; Alex K Konstantinidis; Kent D Stewart; Tatyana Dekhtyar; Teresa Ng; Kerry Swift; Edmund D Matayoshi; Warren Kati; William Kohlbrenner; Akhteruzzaman Molla
Journal:  Virology       Date:  2004-11-24       Impact factor: 3.616

8.  Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

Authors:  Shuwen Liu; Hong Lu; Jinkui Niu; Yujia Xu; Shuguang Wu; Shibo Jiang
Journal:  J Biol Chem       Date:  2005-01-07       Impact factor: 5.157

9.  Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.

Authors:  M Lu; M O Stoller; S Wang; J Liu; M B Fagan; J H Nunberg
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.

Authors:  Kathryn E Follis; Scott J Larson; Min Lu; Jack H Nunberg
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  34 in total

1.  Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.

Authors:  Xiaowen Yu; Lu Lu; Lifeng Cai; Pei Tong; Suiyi Tan; Peng Zou; Fanxia Meng; Ying-Hua Chen; Shibo Jiang
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.

Authors:  Huihui Chong; Xue Yao; Zonglin Qiu; Bo Qin; Ruiyun Han; Sandro Waltersperger; Meitian Wang; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2012-04-16       Impact factor: 5.157

3.  Structural basis of potent and broad HIV-1 fusion inhibitor CP32M.

Authors:  Xue Yao; Huihui Chong; Chao Zhang; Zonglin Qiu; Bo Qin; Ruiyun Han; Sandro Waltersperger; Meitian Wang; Yuxian He; Sheng Cui
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

4.  Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.

Authors:  Dirk Eggink; Ilja Bontjer; Johannes P M Langedijk; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

5.  Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.

Authors:  Yang Su; Huihiui Chong; Shengwen Xiong; Yuanyuan Qiao; Zonglin Qiu; Yuxian He
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

6.  Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.

Authors:  Kun Liu; Hong Lu; Ling Hou; Zhi Qi; Cátia Teixeira; Florent Barbault; Bo-Tao Fan; Shuwen Liu; Shibo Jiang; Lan Xie
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

7.  Immunization with hybrid proteins containing the membrane proximal external region of HIV-1.

Authors:  Nicola Strasz; Vladimir A Morozov; Jürgen Kreutzberger; Martina Keller; Magdalena Eschricht; Joachim Denner
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

8.  DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes.

Authors:  Liang Xu; Lifeng Cai; Xueliang Chen; Xifeng Jiang; Huihui Chong; Baohua Zheng; Kun Wang; Junlin He; Wei Chen; Tao Zhang; Maosheng Cheng; Yuxian He; Keliang Liu
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

9.  Grid-based molecular footprint comparison method for docking and de novo design: application to HIVgp41.

Authors:  Trent E Balius; William J Allen; Sudipto Mukherjee; Robert C Rizzo
Journal:  J Comput Chem       Date:  2013-02-22       Impact factor: 3.376

10.  DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity.

Authors:  Liang Xu; Tao Zhang; Xiaoyu Xu; Huihui Chong; Wenqing Lai; Xifeng Jiang; Chao Wang; Yuxian He; Keliang Liu
Journal:  Nucleic Acid Ther       Date:  2015-08       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.